Active ingredientTerlipressinCat. No. P-T065-001CAS 14636-12-5Family · Pharmaceutical analytical standards
Terlipressin
A peptide analogue of vasopressin synthesised in the mid-1960s in Czechoslovakia by Kasafirek, Rábek, Rudinger and Šorm: it narrows the blood vessels of the splanchnic area, is used against bleeding oesophageal varices and, in the United States since 2022, for hepatorenal syndrome. This family brings together the active ingredient.
Did you know?It is a "hormonogen": the three glycines added at the head of the chain are slowly cleaved off by enzymes, gradually releasing lysine vasopressin and prolonging its effect.
Go to the active ingredient →Active ingredientTerlipressinCat. No. P-T065-001CAS 14636-12-5
Active ingredientTerlipressin AcetateCat. No. P-T065-002CAS 68560-61-2
Active ingredientTerlipressin DiacetateCat. No. P-T065-003CAS 1884420-36-3No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceTerlipressin CRSEDQM code Y0001897Family TerlipressinReference substanceTerlipressin for NMR identification CRSEDQM code Y0001898Family TerlipressinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.